Apellis Pharmaceuticals (APLS) News Today $25.14 +0.10 (+0.40%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$25.27 +0.13 (+0.51%) As of 03/10/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Edgestream Partners L.P.Edgestream Partners L.P. boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 10.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,883 shares of the company's stock after buyingMarch 9 at 5:44 AM | marketbeat.comAnalysts Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $45.53March 9 at 2:01 AM | americanbankingnews.comInsider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells 5,569 Shares of StockApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.March 7, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 5,569 SharesMarch 7, 2025 | insidertrades.comCandriam S.C.A. Has $17.22 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Candriam S.C.A. decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 20.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 539,602 shares of the company's stock after selling 140,456 shares during the periMarch 7, 2025 | marketbeat.comWedbush Has Positive Forecast for APLS Q1 EarningsMarch 7, 2025 | americanbankingnews.comHC Wainwright Issues Optimistic Outlook for APLS EarningsMarch 7, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for APLS Q1 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at HC Wainwright raised their Q1 2025 EPS estimates for Apellis Pharmaceuticals in a research note issued on Monday, March 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.47) per shareMarch 6, 2025 | marketbeat.comWedbush Has Optimistic Outlook of APLS Q1 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush raised their Q1 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Monday, March 3rd. Wedbush analyst L. Chico now anticipates that the companyMarch 6, 2025 | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) StockMarch 6, 2025 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nineteen research firms that are currently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, ten have gMarch 6, 2025 | marketbeat.comApellis Pharmaceuticals: A Mixed BagMarch 5, 2025 | seekingalpha.comApellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan AnalystMarch 5, 2025 | benzinga.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $54.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. lifted their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research report on Tuesday.March 5, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for APLS FY2028 Earnings?March 5, 2025 | americanbankingnews.comWedbush Equities Analysts Boost Earnings Estimates for APLSMarch 5, 2025 | americanbankingnews.comThe Goldman Sachs Group Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PriceMarch 5, 2025 | americanbankingnews.comWedbush Analysts Increase Earnings Estimates for APLSApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at Wedbush lifted their FY2029 EPS estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, March 3rd. Wedbush analyst L. Chico now forecasts that the company will earn $3.79 per share for the year,March 4, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Forecast for APLS EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of Apellis Pharmaceuticals in a report released on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will posMarch 4, 2025 | marketbeat.comRoyal Bank of Canada Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $25.00March 4, 2025 | americanbankingnews.comRoyal Bank of Canada Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PriceRoyal Bank of Canada decreased their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research report on Monday.March 3, 2025 | marketbeat.comThe Goldman Sachs Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $32.00The Goldman Sachs Group dropped their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Monday.March 3, 2025 | marketbeat.comWedbush Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock PriceWedbush reduced their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Monday.March 3, 2025 | marketbeat.comBreaking Down Apellis Pharmaceuticals: 6 Analysts Share Their ViewsMarch 3, 2025 | benzinga.comApellis Pharmaceuticals (APLS) Receives a Hold from ScotiabankMarch 3, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Apellis Pharmaceuticals (NASDAQ:APLS)HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday.March 3, 2025 | marketbeat.comNew York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)New York State Common Retirement Fund lowered its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 87.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,837 shares of the company's stocMarch 3, 2025 | marketbeat.comApellis price target lowered to $30 from $31 at Morgan StanleyMarch 2, 2025 | markets.businessinsider.comApellis price target lowered to $44 from $47 at BofAMarch 2, 2025 | markets.businessinsider.comApellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low - What's Next?March 2, 2025 | americanbankingnews.comApellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call TranscriptMarch 2, 2025 | seekingalpha.comApellis Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 2, 2025 | seekingalpha.comApellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year Low - Time to Sell?Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 52-Week Low - Here's WhyMarch 1, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPSApellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same quarter in the previous year, the firm earned ($0.73) EPS. The company's quarterly revenue was up 45.2% compared to the same quarter last year.March 1, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | insidermonkey.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | msn.comApellis Pharmaceuticals reports Q4 revenue beat, shares fall on Syfovre guidanceFebruary 28, 2025 | ca.investing.comApellis reports Q4 EPS (29c) vs (73c) last yearFebruary 28, 2025 | markets.businessinsider.comApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 28, 2025 | globenewswire.comApellis Pharmaceuticals Q4 2024 Earnings PreviewFebruary 28, 2025 | msn.comApellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comIeq Capital LLC Grows Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Ieq Capital LLC boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1,425.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 126,710 shares of the company's stock after acquiring an additional 118,404February 22, 2025 | marketbeat.comIs Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?February 20, 2025 | msn.comApellis announces EMA validation of Aspaveli indication extension applicationFebruary 20, 2025 | markets.businessinsider.comApellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGNFebruary 20, 2025 | globenewswire.comApellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In JanuaryFebruary 18, 2025 | msn.comApellis Pharmaceuticals (APLS) to Release Earnings on TuesdayApellis Pharmaceuticals (NASDAQ:APLS) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666735)February 18, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest UpdateApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 17,060,000 shares, a drop of 5.4% from the January 15th total of 18,040,000 shares. Based on an average daily trading volume, of 2,640,000 shares, the short-interest ratio is currently 6.5 days.February 18, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Position Raised by Banque Pictet & Cie SABanque Pictet & Cie SA raised its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 31.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,299 shares of the companyFebruary 15, 2025 | marketbeat.comSavant Capital LLC Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Savant Capital LLC boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,525 shares of the company's stFebruary 15, 2025 | marketbeat.com Remove Ads Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.490.50▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼349▲APLS Articles Average Week Remove Ads Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VTRS News RDY News SRPT News PCVX News QGEN News ASND News ROIV News LNTH News RVMD News LEGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts